Mi_onc Profile Banner
Inderjit Mehmi Profile
Inderjit Mehmi

@Mi_onc

Followers
299
Following
2K
Media
26
Statuses
625

Medical Oncologist•The Angeles Clinic and Research Institute•Melanoma•Merkel Cell Cancer•Clinical Trial Concierge

Los Angeles, CA
Joined August 2017
Don't wanna be here? Send us removal request.
@Mi_onc
Inderjit Mehmi
11 months
Need help!.@canyon_bikes .Headset tool GP7203-01, need to borrow/buy.@westlakevillage @CityofTO #roadbike.
0
0
0
@Mi_onc
Inderjit Mehmi
1 year
RT @OmidHamidMD: This is off the shelf bespoke T cell therapy.
0
7
0
@Mi_onc
Inderjit Mehmi
1 year
RT @NEJM: Presented at #ASCO24: . Among patients who received two 3-week cycles of neoadjuvant ipilimumab and nivolumab, the 12-month event….
0
136
0
@Mi_onc
Inderjit Mehmi
1 year
The Boss
Tweet media one
1
3
14
@Mi_onc
Inderjit Mehmi
1 year
RT @OmidHamidMD: Spotlight on @angelesclinic @ASCO #ASCO24 only US site to contribute to NADINA Plenary .#neoadjuvant therapy that will cha….
0
9
0
@Mi_onc
Inderjit Mehmi
1 year
RT @OmidHamidMD: Melanoma Symposium @angelesclinic @AIMatMelanoma March 11th onsite and virtual .Patients, Cargivers, physicians, all welco….
0
10
0
@Mi_onc
Inderjit Mehmi
1 year
RT @OmidHamidMD: Melanoma Education Symposium (Free ) Virtual and In-Person @angelesclinic with @AIMatMelanoma support. Wonderful talks….
0
11
0
@Mi_onc
Inderjit Mehmi
1 year
RT @jtmoyers: Talking about updates in the world of melanoma at MOASC summit in NB tomorrow! @MOASC_Office . I’ll be talking about excitin….
0
8
0
@Mi_onc
Inderjit Mehmi
1 year
What an opportunity to be part of this project! .#clinicaltrials @angelesclinic .@CSCancerCenter.
@rschilsky
Richard Schilsky
1 year
Just published by @ASCO #TAPUR. Olaparib in Patients With Pancreatic Cancer With BRCA1/2 Mutations: Results From the Targeted Agent and Profiling Utilization Registry Study | JCO Precision Oncology
0
3
5
@Mi_onc
Inderjit Mehmi
1 year
@VivekSubbiah
Vivek Subbiah, MD
1 year
Regorafenib in Patients With Solid Tumors With BRAF Alterations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study | JCO Precision Oncology @ASCO @rschilsky @JCOPO_ASCO @OncoAlert .
0
3
5
@Mi_onc
Inderjit Mehmi
1 year
What will you use in 2nd line for melanoma patients, if these data give you pause? Asking for my patients!.
0
0
0
@Mi_onc
Inderjit Mehmi
1 year
RT @OmidHamidMD: Congrats @IovanceBio with @US_FDA approval of TIL therapy! Proud to be part of this revolution @angelesclinic @CSCancerCe….
0
11
0
@Mi_onc
Inderjit Mehmi
2 years
RT @OncLive: RP1 + cemiplimab provided a numerical improvement in response rates vs cemiplimab alone in patients with locally advanced or m….
Tweet card summary image
onclive.com
The combination of RP1 and cemiplimab provided a numerical, but not statistically significant, improvement in response rates vs cemiplimab alone in patients with locally advanced or metastatic...
0
3
0
@Mi_onc
Inderjit Mehmi
2 years
Just learned @Amgen increasing price of #onpro supportive care medicine for patient getting chemotherapy. Is that true? .#breastcancer .#greed<good .@SABCSSanAntonio.
0
0
1
@Mi_onc
Inderjit Mehmi
2 years
RT @OmidHamidMD: Coming soon 2024 @gotoPER Symposium on Melanoma&Cutaneous Malignancies Feb 10 FREE REGISTRATION - USE MY LAST NAME.AS A D….
0
11
0
@Mi_onc
Inderjit Mehmi
2 years
RT @Abbeyandsmokey: November 11 Please help support Ocular melanoma research. If you can't make it to event you can donate at the link bel….
0
1
0
@Mi_onc
Inderjit Mehmi
2 years
RT @OmidHamidMD: Pleased to come into the Natural Killer (NK) therapeutic field with allogenig off the shelf NK cells with @NKGenBiotech @a….
0
6
0
@Mi_onc
Inderjit Mehmi
2 years
Come join and support @ACureInSight1 to help move treatment forward for #ocularmelanoma by raising funds .@CSCancerCenter @angelesclinic .@OmidHamidMD .@jtmoyers.
@ACureInSight1
A Cure In Sight
2 years
One week to go for our LA omies, families, physicians! We hope to SEE you there at #lookinforacure in Santa Monica on Nov 11!. Register, donate/fundraise for #ocularmelanoma in the LA area at @Mi_Onc and all our physicians coming out to support-thank you!
Tweet media one
1
5
6